MedTrace Logo

Lighting Intervention for Cancer-related Fatigue

NCT04827446 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2025-07-09

Study results available
· View outcomes & findings →

Summary

Fatigue is a major problem for cancer patients, and one that can persist long after treatment ends. Recent work has demonstrated that light therapy may mitigate or reduce fatigue levels in both cancer patients and cancer survivors. This protocol seeks to assess how lighting interventions distributed through a mobile app affect fatigue, sleep, and quality of life across three populations of cancer patients: breast cancer and prostate cancer, and patients who have undergone autologous hematopoietic stem cell transplant (HSCT). Participants will be randomized 1:1 to either the interventional SYNC app or to a control app.

Conditions

Interventions

OTHER

Wearable Sensor

Patient is given a wearable device to wear for 12 weeks.

OTHER

Blue-blocking glasses

Patient is given blue-blocking glasses to wear at instructed times.

OTHER

Clear glasses

Patient is given glasses that block no visible light.

OTHER

Full SYNC app

Patient downloads the SYNC app and is given light interventions designed to have a targeted, personalized effect on the circadian clock.

OTHER

"Dummy" SYNC app

Patient downloads the SYNC app and is given light interventions designed to have minimal impact on the circadian clock.

Sponsors & Collaborators

  • Arcascope, Inc

    collaborator UNKNOWN

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Michigan Rogel Cancer Center

    lead OTHER

Principal Investigators

  • Sung Choi, MD · University of Michigan Rogel Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-15
Primary Completion
2023-03-09
Completion
2023-03-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04827446 on ClinicalTrials.gov